Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Completed · Not applicable

Conditions studied: Lymphoma

In brief

The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor. It is usually treated with chemotherapy and radiation. This combination prolongs survival, but about half of patients relapse. The investigators hope that the addition of rituximab will improve the control of the tumor.

Key facts

Study ID

NCT00594815

Run by

Memorial Sloan Kettering Cancer Center

People needed

52

Starts

2002-08-28

Expected to finish

2016-02-23

Last updated by the study team

2017-04-06

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients must have a histologic diagnosis of non-Hodgkin's lymphoma by brain biopsy. Patients who have an inconclusive biopsy or who are not candidates for biopsy may be eligible provided they have a typical cranial magnetic resonance imaging (MRI) or computed tomography (CT) scan and meet at least one of the following two criteria:
• A positive cerebrospinal fluid (CSF) cytology for lymphoma or a monoclonal lymphocyte population as defined by cell surface markers
• A biopsy of the vitreous or uvea demonstrating non-Hodgkin's lymphoma
• A typical MRI/CT scan for primary intracranial lymphoma is defined as the presence of hypo, iso, or hyperdense parenchymal contrast-enhancing (usually homogeneously) mass lesion(s)
• Patients must be HIV-1 negative
• Patients must have a normal or negative pre-treatment systemic evaluation including:
• A bone marrow aspirate and biopsy
• CT scans of the chest, abdomen and pelvis
• Patients must have adequate bone marrow function (defined as peripheral leucocyte count > 4000 cells/mm3 and platelet count > 100,000 cells/mm3), liver function (bilirubin < 2.0 mg and SGOT < 2 times upper limit of normal), and adequate renal function (serum creatinine < 1.5 mg/dl or creatinine clearance > 50 cc/min/1.73M2)
• Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment

You may not qualify if…

• The following would exclude a patient from the study:
• Prior cranial irradiation
• Other active primary malignancy with the exception of basal cell carcinoma of the skin and cervical carcinoma in situ
• Pre-existing immunodeficiency such as renal transplant recipient
• Prior treatment with chemotherapy for CNS lymphoma

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.